Revvity Q3 revenue comes in at $729 million
Key points
- Revvity reported third-quarter 2026 revenue of $729 million, up 4.3% year over year, while adjusted earnings increased to $1.38 per share.
- Pro forma revenue rose 7% to $710 million, and Revvity shares gained approximately 5% in early trading following the earnings announcement.
- Revvity raised its full-year guidance, forecasting approximately $2.86 billion in pro forma revenue and adjusted earnings of $5.40–$5.45 per share.
Revvity (NYSE:RVTY) reported third-quarter 2026 revenue of $729 million, up from $699 million a year earlier, while raising its full-year guidance.
GAAP earnings from continuing operations increased to $0.56 per share from $0.41, while adjusted earnings rose to $1.38 from $1.18.
Pro forma revenue reached $710 million, up 7%, while Revvity forecast approximately $2.86 billion in full-year revenue and adjusted earnings of $5.40–$5.45 per share.
Following the announcement, the Revvity share price was up approximately 5% at $159.29 in early trading.
Revvity reported adjusted operating income of $209 million, up from $182 million, while its adjusted operating margin increased to 28.7% from 26.1%.
The company plans to divest its China Immunodiagnostics business by the end of 2027 and will hold an Investor Day on November 13, 2026.
Frequently asked questions
More from United States
IDEAYA Biosciences Q3 loss widens to $125.7 million
Dynatrace Q2 revenue increases 17% to $580 million
Thomson Reuters records double-digit Q3 revenue growth
Icahn Enterprises unveils $225 million Q3 loss
Keurig Dr Pepper delivers $7.34 billion Q3 sales as earnings beat estimates
Shopify posts double-digit Q3 sales growth as revenue hits $3.74B
